Goblet cell replacement therapy
US10561710B2 · kind B2 · utility
0Cited by
3References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 9, 2018 |
| Grant date | Feb 18, 2020 |
| Priority date | — |
| Expiry date | Jan 9, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.